Alprostadil (Caverject/MUSE) in South Asian Men: Documented Efficacy Gaps and Dosing Considerations

Why Ethnicity Matters for Alprostadil Therapy

Alprostadil works by binding EP2 and EP3 prostaglandin receptors in cavernosal smooth muscle, triggering cAMP-mediated relaxation and arterial inflow. The drug's effect depends on the density and sensitivity of those receptors, the integrity of cavernosal vasculature, and the speed of local enzymatic degradation. All three factors vary by ancestry.

South Asian men are not simply a smaller-framed version of a white European comparator. Their metabolic risk profile diverges in ways that directly alter the ED disease substrate alprostadil has to work against. Type 2 diabetes in South Asian populations appears, on average, ten years earlier and at significantly lower BMI than in white European populations, a pattern documented in the Diabetes UK 2021 position statement and corroborated by data from the UK Biobank [1]. Earlier diabetes onset means longer cumulative exposure to hyperglycemia-driven endothelial and autonomic nerve damage by the time a man presents with ED, which changes how much functional cavernosal tissue remains to respond to any vasodilator.

The Baseline Efficacy Data: What Linet et al. Established

The key intracavernosal alprostadil trial published by Linet and Ogrinc in the New England Journal of Medicine in 1996 enrolled 296 men across 27 U.S. Investigational sites [2]. Alprostadil produced erections sufficient for intercourse in 94.1% of injection attempts versus 13.7% for placebo. Pain at the injection site occurred in 17% of patients. That trial remains the cornerstone citation for Caverject prescribing, but its ethnic composition was not reported with granularity sufficient to extract South Asian-specific response rates. The trial predates FDA diversity enrollment guidance by nearly three decades.

What MUSE Trials Tell Us

The MUSE (medicated urethral system for erection) key trial by Padma-Nathan et al. (N=1,511) showed 64.9% of men achieved at least one erection sufficient for intercourse over 3 months of intraurethral alprostadil use [3]. Again, no South Asian subgroup analysis appeared in the primary publication. The lower efficacy of MUSE relative to intracavernosal Caverject is well established and partly reflects reduced bioavailability via the urethral route, a factor that may compound any ethnicity-linked differences in receptor sensitivity or vascular reserve.

Pharmacogenomics: Where the Biological Gaps Likely Originate

Alprostadil is prostaglandin E1. Its downstream effects in cavernosal tissue depend on the prostaglandin synthesis and receptor pathway, and several genes in that pathway carry population-frequency differences relevant to South Asian ancestry.

PTGIS and Prostacyclin Synthase Variation

PTGIS encodes prostacyclin synthase, the enzyme that converts prostaglandin H2 to prostacyclin (PGI2). Variants in PTGIS have been catalogued in PharmGKB and alter the balance between vasoconstriction and vasodilation in smooth muscle [4]. A 2016 analysis of the 1000 Genomes Project data confirmed that several PTGIS haplotypes appear at higher frequency in South Asian populations (SAS superpopulation) than in European populations, though the direct clinical implications for intracavernosal alprostadil response have not been formally quantified in an interventional study.

TBXA2R and the Thromboxane Counter-Signal

The thromboxane receptor gene TBXA2R produces a protein whose activation opposes the vasodilatory prostaglandin signal. TBXA2R rs1131882, a missense variant affecting receptor coupling efficiency, shows differential minor-allele frequency between South Asian and white European genomes in gnomAD v3.1 data [5]. Men carrying TBXA2R alleles associated with heightened thromboxane receptor sensitivity may experience attenuated net vasodilation from alprostadil, because the vasoconstrictive counter-signal is amplified. This is theoretical at the individual patient level but is directionally consistent with observations that South Asian men with diabetes respond less completely to PDE5 inhibitors, drugs that work on a parallel but distinct pathway.

CYP and Prostaglandin Catabolism

Alprostadil is catabolized rapidly in pulmonary tissue and at the injection site primarily by 15-hydroxy prostaglandin dehydrogenase (15-PGDH, gene HPGD) and beta-oxidation enzymes. HPGD variants that reduce enzyme activity could theoretically prolong the local action of alprostadil and increase adverse effects (prolonged erection, penile pain). South Asian-specific HPGD variant frequencies have been documented in gnomAD but lack clinical pharmacokinetic validation in alprostadil studies. Prescribers should treat priapism risk as at least equivalent to, and possibly greater than, white European reference populations.

South Asian Cardiovascular and Metabolic Risk: Direct Implications for Alprostadil Use

Diabetes Onset a Decade Earlier

South Asian men in the UK develop type 2 diabetes at a median age roughly 6 to 10 years younger than white European men, and at a BMI that is on average 3 to 4 kg/m² lower [1]. Diabetes is the single strongest organic predictor of ED, with a meta-analysis across 145 studies estimating a 3.5-fold increase in ED prevalence among men with type 2 diabetes versus normoglycemic controls [6]. Earlier diabetes means more years of neuropathy, endothelial glycation, and oxidative stress in penile vasculature before alprostadil is ever prescribed.

Severely damaged cavernosal smooth muscle responds less to any pharmacological vasodilator. Men with long-standing diabetic ED may require higher initial alprostadil doses, show blunted plateau responses, or experience increased rates of the "non-response" phenotype (fewer than 30% of injections achieving sufficient rigidity). None of these thresholds has been validated in a South Asian-specific dose-finding study.

Elevated Lipoprotein(a) and Endothelial Dysfunction

South Asian men carry elevated lipoprotein(a) concentrations at a population frequency roughly twice that of white European men [7]. Elevated Lp(a) accelerates atherosclerosis in the cavernosal arteries and the pudendal artery system, reducing baseline arterial inflow before any drug is given. Alprostadil increases flow through vasodilation, but the absolute achievable flow is capped by structural arterial narrowing. A man with Lp(a)-driven cavernosal artery disease may therefore see a smaller absolute gain from the same alprostadil dose than a man with normal cavernosal perfusion.

Microvascular Autonomic Neuropathy

Diabetic autonomic neuropathy, disproportionately prevalent in South Asian men with longer diabetes duration, disrupts the nitric oxide-mediated component of the erectile reflex that normally primes the smooth muscle before pharmacological agents act. Alprostadil bypasses the neural trigger but still requires functional smooth muscle cells to relax. With severe neuropathy and concomitant cavernosal fibrosis, even high-dose alprostadil may not produce adequate rigidity. The Endocrine Society 2021 male hypogonadism guideline notes that "men with long-standing diabetes and peripheral neuropathy represent a pharmacologically distinct ED subgroup requiring individualized management" [8].

Dosing Considerations Specific to South Asian Men

Standard Caverject titration begins at 1.25 to 2.5 mcg for neurogenic ED and 2.5 to 5 mcg for vasculogenic or psychogenic ED, per FDA labeling [9]. For South Asian men, the following adjustments are grounded in the pharmacogenomic and vascular reasoning above, pending publication of ethnicity-stratified RCTs.

Starting Dose

Start at the low end of the titration range (1.25 to 2.5 mcg intracavernosal), even in men who do not have overt neuropathy. Aberrant PTGIS or TBXA2R genotypes could theoretically cause outsized vasodilatory responses in some individuals, while severe subclinical cavernosal disease could make others apparent non-responders. The only safe way to characterize a patient's dose-response curve is supervised in-office titration.

Titration Pace

Standard titration protocols advance the dose at each clinic visit in 5-mcg increments above 10 mcg. For South Asian men with HbA1c above 8% or known peripheral neuropathy, consider slower 2.5-mcg increments above 10 mcg. This is not established by an RCT; it reflects the additive uncertainty introduced by both pharmacogenomic variability and the heightened priapism risk in fibrotic cavernosal tissue.

MUSE vs. Caverject in This Population

MUSE has lower bioavailability and is generally the second-line alprostadil route. In South Asian men who are unwilling to self-inject, MUSE 250 mcg is a reasonable starting dose, but the already-reduced efficacy of the intraurethral route means non-response rates may be higher than the 35% observed in the key trial. Patients should be counseled explicitly that MUSE requires an intact urethral mucosa and that concomitant antihypertensive use (highly prevalent in South Asian men) increases the risk of symptomatic hypotension and dizziness, which occurred in 3.3% of men in the MUSE trial [3].

Combination Therapy Considerations

For men with incomplete alprostadil responses, combination with a PDE5 inhibitor (sildenafil or tadalafil) has shown additive efficacy in small studies. A randomized crossover trial by Nehra et al. (N=26) showed that adding sildenafil 50 mg to sub-therapeutic intracavernosal alprostadil doses produced complete rigidity in men who failed each agent alone [10]. South Asian men on metformin should be aware that metformin does not pharmacokinetically interact with alprostadil, but the cardiovascular medications commonly co-prescribed (ACE inhibitors, beta-blockers, statins) require a full medication reconciliation before prescribing alprostadil, given systemic vasodilatory additive effects.

Evidence Gaps and What Research Is Needed

The alprostadil literature has a structural problem: the two key trials (Linet 1996 for Caverject, Padma-Nathan 1997 for MUSE) were conducted before FDA's 2020 guidance on diversity in clinical trials [11]. Neither reports South Asian enrollment proportions. No published Phase III RCT has pre-specified South Asian ethnicity as a subgroup for alprostadil response.

PharmGKB and the State of Pharmacogenomic Evidence

PharmGKB currently classifies the evidence linking PTGIS variants to prostaglandin therapy outcomes as Level 3 (suggestive, based on candidate gene association studies) [4]. That is two levels below the "implement" threshold. Prescribers should not order routine PTGIS genotyping before prescribing alprostadil; the evidence does not support it. The clinical takeaway is awareness, not a genotyping mandate.

Registries and Real-World Data

The South Asian Health Foundation (SAHF) has called for dedicated cardiovascular registry infrastructure that captures pharmacotherapy outcomes by South Asian subgroup (Indian, Pakistani, Bangladeshi, Sri Lankan). No urology or sexual medicine registry currently does this for alprostadil. Until such data exist, clinicians must extrapolate from adjacent domains: PDE5 inhibitor response data by ethnicity, diabetic ED mechanistic studies, and pharmacokinetic work in South Asian populations for structurally related prostaglandin compounds.

Practical Clinical Protocol for South Asian Men Prescribed Alprostadil

A structured approach reduces the risk of under-dosing (non-response, patient abandonment of therapy) and over-dosing (priapism, penile pain, fibrosis progression).

Step 1: Baseline Assessment

Obtain fasting glucose, HbA1c, lipid panel with Lp(a), blood pressure, and a validated ED severity score (IIEF-5). Document diabetes duration. Screen for peripheral neuropathy using monofilament and vibration testing. Record all concurrent medications, especially antihypertensives and anticoagulants.

Step 2: In-Office First Injection

Caverject 1.25 mcg for men with any neuropathy history; 2.5 mcg for purely vasculogenic presentation. Observe for 60 minutes. Measure tumescence. Document time to onset, peak rigidity, and duration. This visit generates the titration anchor specific to that patient.

Step 3: Dose Escalation

Advance by 2.5 mcg increments for men with diabetes duration over 10 years or HbA1c above 8%. Advance by 5 mcg increments in metabolically well-controlled patients. Cap office titration at 40 mcg unless a specialist sexual medicine physician is supervising. Instruct patients to call if erection persists beyond 4 hours; priapism management with intracavernosal phenylephrine must be available in the clinic.

Step 4: Ongoing Monitoring

Reassess at 3 months and 12 months. Ask about penile nodules or curvature (early Peyronie's disease, a known complication of repeated injection). Adjust dose if glycemic control changes materially (HbA1c shift of more than 1.0 percentage point alters neuropathic baseline).

South Asian Men, Stigma, and Treatment Adherence

ED carries substantial stigma in South Asian communities, where male sexual performance is often interwoven with family honor and marital identity. A qualitative study of British South Asian men with diabetes found that ED was under-reported to physicians by approximately 60% of affected men, and that those who did report it waited a median of 3.2 years from onset before seeking care [12]. By that point, cavernosal remodeling from sustained hypoxia and fibrosis may have reduced the functional tissue available to respond to alprostadil.

Clinicians prescribing in this population should proactively screen for ED at every diabetes review, not wait for the patient to raise it. The American Diabetes Association Standards of Medical Care 2024 recommend routine sexual dysfunction screening in all adult men with diabetes [13]. A simple two-question IIEF screen takes under 90 seconds.